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Abstract 
Background: Plasmodium falciparum resistance to artemisinin emerged in the Greater Mekong Sub-region has been 
associated with mutations in the propeller domain of the kelch gene Pfk13.
Methods: Here the polymorphisms in Pvk12 gene, the orthologue of Pfk13 in Plasmodium vivax, were determined 
by PCR and sequencing in 262 clinical isolates collected in recent years (2012–2015) from the China-Myanmar border 
area.
Results: Sequencing of full-length Pvk12 genes from these isolates identified three synonymous mutations (N172N, 
S360S, S697S) and one non-synonymous mutation M124I, all of which were at very low prevalence (2.0–3.1%). 
Moreover, these mutations were non-overlapping between the two study sites on both sides of the border. Molecular 
evolutionary analysis detected signature of purifying selection on Pvk12.
Conclusions: There is no direct evidence that Pvk12 is involved in artemisinin resistance in P. vivax, but it remains a 
potential candidate requiring further investigation. Continuous monitoring of potential drug resistance in this parasite 
is needed in order to facilitate the regional malaria elimination campaign.
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Background
Although global malaria incidence and death rates have 
decreased in recent years, malaria remains one of the big-
gest threats to populations living within the tropical and 
sub-tropical world. In the Greater Mekong Sub-region 
(GMS) of Southeast Asia, a regional malaria elimination 
plan has been endorsed, aiming to eliminate Plasmodium 
falciparum malaria by 2025 and all malaria by 2030 [1]. 
This ambitious goal is met with challenges, especially 
the recently developed artemisinin resistance among 
P. falciparum populations in this region [2–4]. Further 
complication of the situation results from the increasing 
prevalence of Plasmodium vivax in this region, a parasite 
that is resilient to current control measures [5]. Although 
chloroquine (CQ) remains the primary treatment option 
for P. vivax infections, the emergence of CQ resistance 
has led to the use of artemisinin-based combination ther-
apy (ACT) for the treatment of vivax malaria in Indonesia 
[6]. Monitoring drug resistance in P. vivax populations is 
important for eliminating all malaria from the GMS.
In regions co-endemic for P. falciparum and P. vivax, 
both species can share the same vectors and human 
hosts, and are often subject to similar forces of natural 
selection [7, 8]. Several studies showed that anti-malarial 
drug pressure induces strong selection on both parasite 
species [9, 10]. It is thus assumed that the widespread 
use of ACT for treating P. falciparum infection may exert 
similar collateral selective pressure on P. vivax popula-
tions. Recently, mutations in the propeller domain of 
the Pfk13 gene have been incriminated as important 
determinants of artemisinin resistance in P. falciparum 
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[11–13]. Although ACT is still highly efficacious for 
treating vivax malaria [14, 15], vigilance is required on 
potential emergence of resistance in this parasite [16]. A 
recent study aiming to determine whether similar muta-
tions mediating artemisinin resistance are also present in 
the Pfk13 orthologue in P. vivax (here named Pvk12 gene 
as this gene is located on chromosome 12) found that 
parasites with a Pvk12 mutation (V552I) was circulat-
ing in Cambodia at a very low frequency [17]. To further 
examine the genetic diversity of this gene in the GMS, 
recent collections of clinical isolates of P. vivax from both 
sides of the China-Myanmar border were examined. This 
region has a very long history of artemisinin deployment 
and there is an indication that CQ efficacy for treating P. 
vivax malaria is decreasing [18]. Here Pvk12 genes in 262 
P. vivax parasite isolates were sequenced and molecular 
evolution analyses were performed to determine whether 
this gene is subject to potential selection.
Methods
Collection of parasite clinical isolates
Plasmodium vivax samples were collected from malaria 
patients with acute P. vivax infections attending malaria 
clinics located on both sides of the China-Myanmar 
border. Plasmodium vivax infection was diagnosed by 
microscopy of Giemsa-stained thick and thin blood 
films. A total of 162 samples were obtained from 13 clin-
ics around Laiza township, Kachin State, Myanmar dur-
ing the high transmission season (June to September) in 
2015. One-hundred samples were collected in 2012–2013 
from Tengchong County, Yunnan Province, China. The 
standard treatment for P. vivax malaria is CQ (25  mg/
kg, divided into three days) and primaquine (0.25  mg/
kg/day for 14 days in Kachin State; 0.375 mg/kg/day for 
8  days in Yunnan Province) [19]. On both sides of the 
border, malaria transmission has been reduced in recent 
years [20, 21]. Especially, P. falciparum malaria incidence 
has experienced a sharp decline [22, 23], possibly due to 
the extensive use of ACT. To collect finger-prick blood 
on filter papers, written informed consent was obtained 
from the participants or their guardians. This study was 
approved by the Institutional Review Board of Kunming 
Medical University.
DNA extraction, gene amplification and sequencing 
analysis
Genomic DNA was extracted using the High Pure PCR 
Template Preparation Kit (Roche, Germany) and eluted in 
50 µl of H2O. Parasite samples were genotyped by PCR/
RFLP of two polymorphic genes msp3α and msp3β to dis-
tinguish single from mixed-strain infections [24, 25]. Only 
infections containing single P. vivax strains by genotyping 
were used for sequencing analysis. The full-length Pvk12 
gene was amplified by nested PCR using 2X TSINGKE™ 
Master Mix (Beijing Tsingke Biotech, China) contain-
ing high-fidelity Pfu DNA polymerase with outer prim-
ers K13P1F (5′-CCATACTGGCTGCACCTGCTT-3′) 
and K13P1R (5′-GTAGTGGCAGTGGAGGAGAG-3′), 
and nested primers K13P2F (5′-CCACGGAACAGAT-
GAATCTTC-3′) and K13P2R (5′-AAACCCGAGAAA-
GTTGTAGCA-3′). PCR reactions were performed in 25 
with 1 µl DNA template, 0.5 μM of each primer, 12.5 μl 
Master Mix, and 10.5 μl H2O. For the primary reaction the 
following cycling parameters were used: 5 min at 94 °C, 35 
cycles at 94 °C for 30 s, 63 °C for 30 s, 72 °C for 90 s, and 
final extension for 7  min at 72  °C. For nested PCR, 1  μl 
primary PCR product was used as template and the fol-
lowing cycling parameters were used: 5 min at 94  °C, 35 
cycles at 94 °C for 30 s, 57 °C for 30 s, 72 °C for 90 s, and 
final extension for 7  min at 72  °C. Sequencing was per-
formed on both strands and sequences were assembled by 
using DNASTAR (WI, USA) with manual editing. Align-
ment of DNA sequences were performed using MEGA 6.0 
[26] and BioEdit (version 7.2.5) with the Pvk12 sequence 
of Salvador I (Sal-I) genome (PVX_083080) as the refer-
ence. The five haplotypes of Pvk12 gene derived from this 
study have been submitted to GenBank under the acces-
sion numbers (KX961684–KX961688).
Molecular evolutionary analysis of Pvk12
A total of 333 full-length Pvk12 sequences were analysed, 
of which 262 samples were from the current study. The 
remaining 71 sequences including four from Oceania, 
11 from North America, one from Africa, 34 from South 
America, and 21 from Southeast Asia were downloaded 
from PlasmoDB [27], as a result from the P. vivax hybrid 
selection sequencing project [28]. The sequences were 
aligned with the Sal-I reference sequence using ClustalW 
implemented in MEGA 6.0. SNP information was used 
to generate haplotypes and to calculate haplotype diver-
sity. To determine the genetic diversity of Pvk12 gene, the 
average pairwise nucleotide diversity (π) and the average 
number of segregating sites (θ) were calculated. To detect 
signatures of natural selection, the number of non-syn-
onymous substitutions per non-synonymous site (dN) 
and synonymous substitutions per synonymous site (dS) 
were estimated. A codon-based Z test was performed to 
calculate possible departure from neutrality with the var-
iance of difference between dN and dS being computed 
by the bootstrap method with 500 replicates [29]. This 
neutrality test was further corroborated using Tajima’s D 
and Fu’s Fs tests. All molecular evolution tests were per-
formed using MEGA 6.0. Pairwise linkage disequilibrium 
(LD) was also used to determine the degree of random 
association between different mutations within this gene. 
The correlation coefficient (R2) between paired alleles 
Page 3 of 6Deng et al. Malar J  (2016) 15:528 
was estimated using DNASP v5.0 and Arlequin 3.5, and 
the significance of each association was determined using 
the χ2 test after Bonferroni correction.
Results
Genetic diversity of Pvk12 from the two geographical 
regions
Two hundred and sixty two full-length Pvk12 sequences 
(2139 bp) in parasite samples from two regions along the 
China-Myanmar border were obtained. Compared with 
the Sal-I reference sequence, one synonymous SNP at 
nucleotide 2091 was observed in five (3.1%) isolates from 
the Kachin samples, while two different synonymous 
SNPs at nucleotide 516 and 1080, respectively, were iden-
tified in four (2%) isolates from the Tengchong samples 
(Table 1; Fig. 1). In addition, one non-synonymous muta-
tion, M124I, was found in two isolates from Tengchong, 
whereas no non-synonymous mutation was identified in 
the Kachin samples. Altogether, the frequency of para-
sites containing Pvk12 mutations was very low, making 
up of only 4.2%. In comparison, 71 downloaded Pvk12 
sequences were all the same as the wild type reference 
sequence. Consistent with this result, genetic diversity 
of Pvk12 gene represented by the π and θ values was 
extremely low for the China-Myanmar border samples 
(Table  2). Similarly, only five haplotypes were observed 
with the wild type as the predominant. Among the par-
asite isolates from Tengchong, four haplotypes were 
observed, giving a haplotype diversity of 0.116. The hap-
lotypes of these two regions were completely different 
without overlap. Except for the wild type, other haplo-
types containing single mutations all were very rare. Fur-
thermore, pairwise LD analysis revealed no significant 
associations between different alleles (see Additional files 
1, 2; P > 0.05, χ2 test).
Signature of purifying selection
Several molecular evolutionary analyses were performed 
to assess the role of natural selection on Pvk12. When all 
samples were combined, both Tajima’s D and Fu and Li’s 
Fs were significantly deviated from neutrality (Table  2) 
and suggested of purifying selection. The dN–dS analysis 
also showed higher prevalence of synonymous than non-
synonymous mutations, albeit the value was not statisti-
cally significant. Interestingly, when samples from the two 
regions were analysed separately, purifying selection on 
this gene was only evident in isolates from Tengchong, 
China (Table 2). Although the Tajima’s D and Fu and Li’s 
F values for the Kachin samples did not reach significance, 
they had the same trend as for the Tengchong samples.
Discussion
Mutations in the propeller domain of Pfk13 gene have 
been associated with artemisinin resistance in P. falcipa-
rum, which is manifested as delayed parasite clearance 
after artemisinin treatment [11, 12]. A recent analysis of 
worldwide P. falciparum populations identified numerous 
Table 1 Prevalence of  point mutations in  the Pvk12 
gene of  Plasmodium vivax isolates from  the two regions 
along the China-Myanmar border
Point mutations Prevalence [N (%)]
Nucleotide Amino acid Kachin (N = 162) Tengchong (N = 100)
G372A M124I – 2 (2.0%)
C516T N172N – 2 (2.0%)
C1080T S360S – 2 (2.0%)
C2091T S697S 5 (3.1%) –
Fig. 1 Example chromatograms of the Pvk12 gene showing synonymous mutations at nucleotide positions 516, 1080 and 2091, and non-synony-
mous mutations at position 372. Included are the Pvk12 sequences in the Sal-I strain and parasite isolates TV105, TV133, TV29 and LZCH-1493
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non-synonymous mutations with marked geographic 
disparity in their frequency and distribution, which may 
reflect the demographic history of the parasite popu-
lations and different drug use histories [30]. In sharp 
contrast, studies conducted to date in the GMS, where 
artemisinin resistance has emerged in P. falciparum, 
showed a highly conserved Pvk12 gene [17, 31]. In Cam-
bodia where Pfk13 mutations were highly prevalent, anal-
ysis of 284 P. vivax isolates identified only two isolates 
with a non-synonymous mutation, V552I [17], although 
these parasites may have been exposed to higher drug 
selection pressure. Similarly, analysis of 66 P. vivax sam-
ples from central China identified a G581R mutation in 
one sample (Wang et  al. unpublished). In comparison, 
this analysis of 262 full-length Pvk12 sequences only 
identified that two parasite isolates (2%) collected from 
Yunnan’s Tenchong County contained a non-synony-
mous mutation, M124I, which is located near the N-ter-
minal region. Thus, mutations identified here, being 
outside of the propeller domain, are unlikely involved in 
artemisinin resistance even if Pvk12 is presumed to play 
an analogous role to Pfk13 in resistance. Furthermore, 
although the recent genomic studies of world P. vivax 
populations identified five non-synonymous mutations 
in Pvk12 (N25I, S253T, V552I, V652L, and A710E) in 
228 samples, all of these mutations were rare mutations 
[31]. Specifically, the N25I mutation was identified only 
in 2% of the western Thai samples (N  =  89), whereas 
the S253T mutation was found only in 8% of the Papua 
Indonesia samples (N = 55), and each of the three other 
mutations was present only in one sample. Though some 
of these mutations are located in the propeller domain, 
their functions still need to be evaluated individually as 
mutations within the propeller domains such as A578S in 
Pfk13 may not necessarily be associated with artemisinin 
resistance [12].
The observed deficiency of mutations in the Pvk12 
gene is in sharp contrast to Pfk13 from the sympatric P. 
falciparum populations [11, 30]. While it is unknown 
whether Pvk12 and Pfk13 are functionally equivalent, 
the high level of conservation of Pvk12 suggests that (1) 
Pvk12 may play a different role in parasite biology even 
if Pvk12 has a similar function to Pfk13 and its conser-
vation is maintained by functional constraints (purifying 
selection) and, (2) if Pvk12 is involved in artemisinin 
resistance, the different mutation rates in Pfk13 and 
Pvk12 may suggest different drug selection pressures on 
these two parasites. Likewise, there is evidence that pfk13 
is under natural selection as non-synonymous mutations 
exceed synonymous mutations [32]. In contrast, Pvk12 
appears to be under purifying selection, though the lim-
ited polymorphisms at four positions of Pvk12 in 11 of 
262 samples analyzed here preclude a robust evolutionary 
analysis. To date the functions of Plasmodium k13 ortho-
logues are still unknown, but their similarity in sequence 
to the human KEAP1 protein, which is involved in the 
regulation of the antioxidant responses [33], suggest that 
they might have similar functions. In P. falciparum, it was 
found that the Pfk13 is linked to the phosphotidylinosi-
tol-3-phosphate kinase (PI3K) pathway and artemisinin-
conferring Pfk13 mutations are associated with increased 
PI3K activity and higher levels of the product phosphati-
dylinositol-3-phosphate [34]. If a similar pathway link-
ing k13 and PI3K works in both parasite species, drug 
selections may be imposed on different enzymes within 
the same pathway. Interestingly, divergent selections 
have been identified on the phosphoinositide-dependent 
kinase PDK-1 among P. vivax populations, an enzyme 
participating in the PI3K pathway [28]. It is unknown 
whether this observation suggests that artemisinin family 
drugs might have acted on the PvPDK-1 gene instead of 
Pvk12 gene in P. vivax. It is also possible that the highly 
conserved Pvk12 gene among worldwide P. vivax popu-
lations may suggest that Pvk12 may have nothing to do 
with artemisinin resistance, like that the pvcrt-o gene is 
not a major player in CQ resistance in P. vivax as com-
pared to the critical role of its orthologue pfcrt in mediat-
ing CQ resistance in P. falciparum.
Mutations within Pvk12, though rare, displayed quite 
significant geographical disparities. Three different 
non-synonymous mutations have been identified in 
parasite populations from different parts of the GMS 
[17, 31]. Considering evidence of independent emer-
gence of artemisinin resistance-conferring Pfk13 muta-
tions in different areas of the GMS [35], this difference 
in Pvk12 may indicate different demographic histories 
and the presence of gene flow barriers among these 
parasite populations. It could also reflect different drug 
Table 2 Genetic diversity and summary statistics of Pvk12 gene
H number of haplotypes
* P < 0.05
Regions No. isolates H θ π dN–dS Tajima’s D Fu’s Fs
Kachin 162 2 0.000083 0.000028 −1.071 −0.69076 −0.91123
Tengchong 100 4 0.000271 0.000056 −1.275 −1.42652* −3.88033*
Total 262 5 0.000304 0.000039 −1.579 −1.49534* −6.52209*
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use histories for P. falciparum malaria, which may have 
exerted collateral selection on P. vivax, given that the 
front-line treatment for P. vivax malaria in most GMS 
countries remains as CQ and primaquine. Nevertheless, 
the collateral selection by artemisinins in the case of 
mixed P. falciparum/P. vivax infections that are treated 
by ACT should be minimal. Plasmodium vivax parasites 
reappearing after ACT treatment may be the relapsing 
parasites resulted from the awakening hypnozoites, and 
thus further transmission probably will be from these 
unselected parasites. In this regard, future surveillance 
on artemisinin resistance in P. vivax may need to focus 
on areas such as Indonesia where ACT has replaced CQ 
for treatment of vivax malaria, though recent analysis of 
a limited number of samples did not detect mutations in 
the propeller domain of Pvk12 in the Papua Indonesia 
samples [31].
Conclusions
Pvk12 only displayed very limited genetic diversity in 
parasite populations from the China-Myanmar border 
area, as well as from other regions of the GMS, where 
artemisinin resistance is P. falciparum has emerged 
recently. Pvk12 is not implicated in drug resistance nor 
is it recommended for molecular surveillance for drug 
resistance.
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